Asahi Kasei Completes Aicuris Acquisition for €780M

Asahi Kasei has completed the acquisition of Aicuris, a pharmacy business in Germany, for about €780 million. Asahi Kasei acquisitions add Aicuris Anti-infective Cures AG’s antiviral pipeline and scientific capabilities to strengthen severe infectious diseases and specialty pharma development. The Aicuris acquisition expands Asahi Kasei’s anti-infective portfolio with three assets spanning marketed and clinical-stage programs, including Prevymis royalty revenue and pritelivir and AIC468 in development. This strategic acquisition is a healthcare M&A merger acquisition by a strategic buyer, building a global specialty pharmaceutical platform in transplant and immunocompromised patient settings.